2015
Liver Fibrosis Progression in Hepatitis C Virus Infection After Seroconversion
Butt AA, Yan P, Re V, Rimland D, Goetz MB, Leaf D, Freiberg MS, Klein MB, Justice AC, Sherman KE. Liver Fibrosis Progression in Hepatitis C Virus Infection After Seroconversion. JAMA Internal Medicine 2015, 175: 178-185. PMID: 25485735, PMCID: PMC5017246, DOI: 10.1001/jamainternmed.2014.6502.Peer-Reviewed Original ResearchConceptsDiagnosis of cirrhosisLiver fibrosis progressionHepatic decompensation eventsDevelopment of cirrhosisFibrosis progressionHCV controlHepatic decompensationDecompensation eventsLiver fibrosisNegative HCV antibody test resultPositive HCV RNA test resultLower mean body mass indexHCV antibody test resultHCV RNA test resultsNational Veterans Affairs databaseHepatitis C virus infectionMean body mass indexHigher serum aminotransferase levelsHCV Infected VeteransRNA test resultsC virus infectionFIB-4 scoreFibrosis-4 indexSerum aminotransferase levelsMonths of follow
2014
Virologic response and haematologic toxicity of boceprevir‐ and telaprevir‐containing regimens in actual clinical settings
Butt AA, Yan P, Shaikh OS, Freiberg MS, Re V, Justice AC, Sherman KE, Team T. Virologic response and haematologic toxicity of boceprevir‐ and telaprevir‐containing regimens in actual clinical settings. Journal Of Viral Hepatitis 2014, 22: 691-700. PMID: 25524834, PMCID: PMC5020421, DOI: 10.1111/jvh.12375.Peer-Reviewed Original ResearchConceptsSustained virologic responsePEG/RBVHaematologic toxicityActual clinical settingsSVR ratesVirologic responseClinical settingHaematologic adverse eventsHCV Infected VeteransInterferon/ribavirinHCV genotype 1HCV RNA valuesPivotal clinical trialsHepatitis C virusBaseline cirrhosisHIV coinfectionPrimary endpointTreatment-naïveAdverse eventsC virusClinical trialsGenotype 1Genotype 1aSevere toxicityBoceprevir
2009
Hepatitis C Virus Infection and the Risk of Coronary Disease
Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC. Hepatitis C Virus Infection and the Risk of Coronary Disease. Clinical Infectious Diseases 2009, 49: 225-232. PMID: 19508169, PMCID: PMC3077953, DOI: 10.1086/599371.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseHepatitis C virus infectionC virus infectionTraditional risk factorsHigh riskHCV infectionControl subjectsRisk factorsVirus infectionRisk of CADMean total plasma cholesterolLow-density lipoprotein cholesterolCox proportional hazards modelHCV Infected VeteransTotal plasma cholesterolFavorable risk profileProportional hazards modelVeterans Affairs facilitiesLower lipid levelsLipoprotein cholesterolObservational cohortRenal failureArtery diseaseCoronary diseaseMultivariable analysis